B of A Securities analyst Alex Stranahan maintains Sana Biotechnology (NASDAQ:SANA) with a Buy an

Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's af

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.13) per share which beat the analy

Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has been assigned an average rating of "Mo

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid a

Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the compan

 Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Tri

Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Tria

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients thr

SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focuse

Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused

The investment, including participation based on interest received from RA Capital Management, combi

SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focuse

Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transc

Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients thro

SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.14) per share which beat the analy

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused

SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focus

Kailera Therapeutics prices $625 million IPO, advances GLP-1 obesity pipeline as trial data highligh

Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TV

Wedbush analyst Martin Fan maintains Sana Biotechnology (NASDAQ:SANA) with a Outperform and rais

Bloom Energy (BE) rose in pre-market trading as it announces expanded partnership with Oracle (ORCL)

Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data and the hea

Stock futures mixed, Citigroup and Wells Fargo report earnings, Sana Biotechnology announces collabo

On April 10, 2026 (the "Effective Date"), Sana Biotechnology, Inc. (the "Company") e

 Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of

U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline

Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has earned a consensus rating of "Moderate

Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript

Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting

Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

HC Wainwright & Co. analyst Emily Bodnar maintains Sana Biotechnology (NASDAQ:SANA) with a Bu

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modi

SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focuse

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients thr

B of A Securities maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and raises the price targe

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow w

Eric Jackson names BTQ his next 100-bagger, betting it can stop quantum computers from "hacking

Wedbush analyst Martin Fan maintains Sana Biotechnology (NASDAQ:SANA) with a Outperform and rais

HC Wainwright & Co. analyst Emily Bodnar maintains Sana Biotechnology (NASDAQ:SANA) with a Bu

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.15) per share which beat the analy